Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease severity of children with hereditary spherocytosis predicts the clinical course of aplastic crisis.

European journal of pediatrics·2026
Same author

An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non-malignant hematological diseases.

HemaSphere·2026
Same author

A Europe-wide provider perspective of healthcare services for adolescent and young adult patients with haematological conditions: a survey from the Adolescent and Young Adult Taskforce of the European Hematology Association.

EClinicalMedicine·2026
Same author

Meningitis outbreak in Gaza: the role of malnutrition, displacement and attacks on healthcare.

BMJ global health·2026
Same author

Hospital functionality in the Gaza Strip: analysis of the World Health Organization health resources and services availability monitoring system database, 7 Oct 2023 to 31 Oct 2024.

Conflict and health·2026
Same author

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Frontiers in oncology·2026

Related Experiment Video

Updated: Mar 9, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Evaluating platelet function disorders in children with bleeding tendency - A single center study.

Osama Tanous1, Orna Steinberg Shemer2,3, Joanne Yacobovich2,3

  • 1a Pediatric Ward A , Haemek Medical Center , Afula , Israel.

Platelets
|January 7, 2017
PubMed
Summary

Light transmission aggregometry (LTA) effectively diagnoses platelet function disorders in children with bleeding tendencies. The platelet function Analyzer 100 (PFA-100) showed limited sensitivity as a screening tool in this pediatric population.

Keywords:
Bleeding disordersPFA-100closure timelight transmission aggregometrypediatrics

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K

Area of Science:

  • Pediatric Hematology
  • Hemostasis and Thrombosis
  • Diagnostic Accuracy

Background:

  • Platelet function disorders (PFDs) are a common cause of mild bleeding, often undetected by standard screening.
  • Accurate diagnosis of PFDs in pediatric patients is crucial but challenging due to limited validation data for diagnostic tests.
  • Light transmission aggregometry (LTA) is the gold standard, while closure time (CT) via PFA-100 is a newer, less validated method.

Purpose of the Study:

  • To evaluate the diagnostic utility of LTA and PFA-100 for identifying PFDs in children presenting with bleeding tendencies.
  • To assess the correlation between bleeding severity scores and the results of LTA and PFA-100 in pediatric patients.

Main Methods:

  • Retrospective analysis of 137 pediatric patients (1 month-18 years) who underwent LTA testing between 2006-2015.
  • Exclusion of patients with thrombocytopenia, thrombocytosis, or coagulation factor deficiencies.
  • Assessment of bleeding severity using a pediatric bleeding score; comparison of LTA and PFA-100 results with bleeding scores.

Main Results:

  • Abnormal LTA results were observed in 40% of pediatric patients, significantly correlating with higher bleeding scores (≥2).
  • Prolonged CT was found in 23% of patients, but showed no significant correlation with bleeding severity or LTA results.
  • No correlation was found between abnormal LTA and prolonged CT, indicating differing diagnostic capabilities.

Conclusions:

  • LTA is a valuable diagnostic tool for identifying platelet aggregation defects in children with bleeding tendencies, diagnosing 40% of cases.
  • Abnormal LTA results were significantly more prevalent in children with moderate to severe bleeding tendencies (score ≥2).
  • PFA-100 (CT) demonstrated insufficient sensitivity as a screening tool for PFDs in this pediatric cohort, unlike LTA.